Pluvicto for prostate cancer: what to know

Before treatment, the team reviews scans, laboratory results, medicines, and symptoms. The targeting part is designed to deliver radiation close to cells that carry the marker, while normal tissues can still receive exposure. Monitoring may include blood counts and kidney tests because treatment can affect bone marrow or renal function. The team will explain hydration, toilet precautions, contact guidance, and follow-up in language suited to your home situation.

Give the nuclear medicine team a complete list of medicines, supplements, and recent treatments. Tell them about kidney problems, urinary difficulty, bleeding, infection symptoms, or difficulty managing fluids independently. Ask what to bring, how to arrange transport, and how long the radiation-safety instructions apply to your circumstances. Bone-strengthening therapy or other treatments may be considered alongside cancer care, but the combination must be coordinated.

Contact the treatment service promptly for fever, unusual bleeding or bruising, persistent vomiting, reduced urine, severe weakness, or worsening pain. Seek urgent help for inability to pass urine, severe breathlessness, collapse, or new confusion. Follow the service’s specific instructions about whom to call because symptoms may need assessment between scheduled visits.

Ask whether your scans show the treatment target, why Pluvicto is being recommended now, and how kidney function and blood counts will be monitored. Discuss expected visit arrangements, radiation-safety steps at home, effects on existing medicines, and what alternatives such as radiotherapy or other prostate cancer treatments might be appropriate.